在CIDP的Claseprubart第3阶段试验之后,Dianthus治疗术公司的库存在达到关键临时目标后上升,没有产生严重的副作用。 Dianthus Therapeutics' stock rose after its Phase 3 trial for Claseprubart in CIDP met key interim goals with no serious side effects.

Dianthus Therapeutics在CIDP中Claseprubart的三期CAPTIVATE试验符合临时开放物标准后，股价上涨，A部分已有20名确诊响应者。 Dianthus Therapeutics shares rose after its Phase 3 CAPTIVATE trial for Claseprubart in CIDP met interim GO criteria, with 20 confirmed responders in Part A. 该公司将把试验范围扩大到A部分多达256名病人,B部分随机将128名病人列入B部分,没有发生与治疗有关的严重不利事件。 The company will expand the trial to up to 256 patients in Part A and randomize 128 in Part B, with no serious treatment-related adverse events. B部分的上线数据预计到2026年底将获得。 Top-line data from Part B are expected by end of 2026. 迪安修斯计划在2026年中期之前在全般性肌痛性脑膜炎中进行注册试验,并预计在2026年底获得多焦点运动神经病症的第二阶段结果. Dianthus plans a registrational trial in generalized myasthenia gravis by mid-2026 and expects Phase 2 results for multifocal motor neuropathy in late 2026. 该公司2025年结束时的现金为5.14亿美元,支持2028年的业务。 The company ended 2025 with $514 million in cash, supporting operations through 2028.